HU9601419D0 - Synergetic pharmaceutical compositions for treating parkinson-disease - Google Patents

Synergetic pharmaceutical compositions for treating parkinson-disease

Info

Publication number
HU9601419D0
HU9601419D0 HU9601419A HUP9601419A HU9601419D0 HU 9601419 D0 HU9601419 D0 HU 9601419D0 HU 9601419 A HU9601419 A HU 9601419A HU P9601419 A HUP9601419 A HU P9601419A HU 9601419 D0 HU9601419 D0 HU 9601419D0
Authority
HU
Hungary
Prior art keywords
disease
pharmaceutical compositions
treating parkinson
parkinson
synergetic
Prior art date
Application number
HU9601419A
Other languages
English (en)
Inventor
Bertrand L Chenard
Frank S Menniti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE69532482T priority Critical patent/DE69532482T2/de
Priority to JP8535520A priority patent/JPH11505828A/ja
Priority to ES95918111T priority patent/ES2211904T3/es
Priority to US08/930,599 priority patent/US6258827B1/en
Priority to MX9709112A priority patent/MX9709112A/es
Priority to AT95918111T priority patent/ATE258067T1/de
Priority to PCT/IB1995/000398 priority patent/WO1996037226A2/en
Priority to EP95918111A priority patent/EP0828513B1/en
Priority to RU96109832/14A priority patent/RU2176145C2/ru
Priority to DK95918111T priority patent/DK0828513T3/da
Priority to PT95918111T priority patent/PT828513E/pt
Priority to CA002219911A priority patent/CA2219911C/en
Priority to TW085105153A priority patent/TW470740B/zh
Priority to IL11832896A priority patent/IL118328A/en
Priority to CO96026135A priority patent/CO4700422A1/es
Priority to NO962130A priority patent/NO962130L/no
Priority to CN96107556A priority patent/CN1159325A/zh
Priority to AU54519/96A priority patent/AU696258B2/en
Priority to HU9601419A priority patent/HUP9601419A3/hu
Priority to PL96314413A priority patent/PL314413A1/xx
Priority to TR96/00436A priority patent/TR199600436A2/xx
Priority to NZ286656A priority patent/NZ286656A/en
Application filed by Pfizer filed Critical Pfizer
Priority to SG1996009888A priority patent/SG45479A1/en
Priority to CZ961524A priority patent/CZ283979B6/cs
Priority to BR9602485A priority patent/BR9602485A/pt
Publication of HU9601419D0 publication Critical patent/HU9601419D0/hu
Publication of HUP9601419A2 publication Critical patent/HUP9601419A2/hu
Priority to FI974323A priority patent/FI974323A/fi
Publication of HUP9601419A3 publication Critical patent/HUP9601419A3/hu

Links

Classifications

    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10H—ELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00—Instruments in which the tones are generated by means of electronic generators
    • G10H5/10—Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
HU9601419A 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease HUP9601419A3 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
JP8535520A JPH11505828A (ja) 1995-05-26 1995-05-26 パーキンソン症候群の治療用の選択的ｎｍｄａアンタゴニスト含有組合せ
ES95918111T ES2211904T3 (es) 1995-05-26 1995-05-26 Combinaciones para el tratamiento del parkinsonismo que contienen antagonistas selectivos de nmda.
US08/930,599 US6258827B1 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective NMDA antagonists
MX9709112A MX9709112A (es) 1995-05-26 1995-05-26 Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato.
AT95918111T ATE258067T1 (de) 1995-05-26 1995-05-26 Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
DE69532482T DE69532482T2 (de) 1995-05-26 1995-05-26 Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
EP95918111A EP0828513B1 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
RU96109832/14A RU2176145C2 (ru) 1995-05-26 1995-05-26 Синергическое лечение паркинсонизма
DK95918111T DK0828513T3 (da) 1995-05-26 1995-05-26 Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister
PT95918111T PT828513E (pt) 1995-05-26 1995-05-26 Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo
CA002219911A CA2219911C (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
TW085105153A TW470740B (en) 1995-05-26 1996-04-30 Pharmaceutical compositions for synergistic treatment of Parkinsonism
IL11832896A IL118328A (en) 1995-05-26 1996-05-20 Use of a combination of a selective antagonist for N-methyl-D-aspartate in the forebrain and an amplifier for re-stimulation to stimulate, in order to prepare a pharmaceutical preparation for the treatment of Parkinson's disease
CO96026135A CO4700422A1 (es) 1995-05-26 1996-05-23 Producto farmaceutico que comprende una cantidad sinergica de un antagonista selectivo de nmda del cerebro anterior y un compuesto capaz de aumentar la retroalimentacion excitadora de un nucleo lateral ventral del talamo al cortex para el tratamiento
NZ286656A NZ286656A (en) 1995-05-26 1996-05-24 Pharmaceutical compositions comprising a forebrain selective NMDA antagonist and an excitatory feedback enhancing agent used in treating Parkinsons Disease
AU54519/96A AU696258B2 (en) 1995-05-26 1996-05-24 Synergistic treatment for Parkinsonism
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease
PL96314413A PL314413A1 (en) 1995-05-26 1996-05-24 Synergistic treatment of parkinsonism
TR96/00436A TR199600436A2 (tr) 1995-05-26 1996-05-24 Parkinsonizm icin sinerjistik tedavi.
SG1996009888A SG45479A1 (en) 1995-05-26 1996-05-24 Synergistic treatment for parkinsonism
NO962130A NO962130L (no) 1995-05-26 1996-05-24 Synergistisk behandling av Parkinsons sykdom
CN96107556A CN1159325A (zh) 1995-05-26 1996-05-24 帕金森氏综合症的协同治疗
CZ961524A CZ283979B6 (cs) 1995-05-26 1996-05-27 Farmaceutický prostředek pro léčení Parkinsonovy choroby
BR9602485A BR9602485A (pt) 1995-05-26 1996-05-27 Método para o tratamento da doença de Parkinson composição farmacêutica primeira composição farmacêutica e método para a obtenção de efeito antiParkinson
FI974323A FI974323A (fi) 1995-05-26 1997-11-25 Selektiivisiä NMDA-antagonisteja sisältäviä yhdistelmiä parkinsonismin hoitoa varten

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (3)

Publication Number Publication Date
HU9601419D0 true HU9601419D0 (en) 1996-07-29
HUP9601419A2 HUP9601419A2 (en) 1997-09-29
HUP9601419A3 HUP9601419A3 (en) 1998-01-28

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Country Status (26)

Country Link
US (1) US6258827B1 (hu)
EP (1) EP0828513B1 (hu)
JP (1) JPH11505828A (hu)
CN (1) CN1159325A (hu)
AT (1) ATE258067T1 (hu)
AU (1) AU696258B2 (hu)
BR (1) BR9602485A (hu)
CA (1) CA2219911C (hu)
CO (1) CO4700422A1 (hu)
CZ (1) CZ283979B6 (hu)
DE (1) DE69532482T2 (hu)
DK (1) DK0828513T3 (hu)
ES (1) ES2211904T3 (hu)
FI (1) FI974323A (hu)
HU (1) HUP9601419A3 (hu)
IL (1) IL118328A (hu)
MX (1) MX9709112A (hu)
NO (1) NO962130L (hu)
NZ (1) NZ286656A (hu)
PL (1) PL314413A1 (hu)
PT (1) PT828513E (hu)
RU (1) RU2176145C2 (hu)
SG (1) SG45479A1 (hu)
TR (1) TR199600436A2 (hu)
TW (1) TW470740B (hu)
WO (1) WO1996037226A2 (hu)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
HUP0004900A3 (en) * 1997-10-24 2002-03-28 Warner Lambert Co Pharmaceutical compositions for treating disease-related or drug-induced dyskinesias containing piperidine derivatives as nmda receptor antagonist as active ingredient
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
JP2003512422A (ja) 1999-10-29 2003-04-02 メルク シャープ エンド ドーム リミテッド ベンズイミダゾールｎｍｄａ／ｎｒ２ｂアンタゴニストを使用する疼痛の治療方法
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
CZ20032258A3 (cs) 2001-02-23 2004-01-14 Merck & Co., Inc. N-substituované nearylové heterocyklické sloučeniny
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
US7375136B2 (en) 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
JP2005511478A (ja) 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
CA2501348A1 (en) * 2002-10-08 2004-04-22 Allergan, Inc. Treatment of dementia and parkinson's disease
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
EP1667630A4 (en) * 2003-09-04 2008-07-23 Univ Texas METHOD AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DISEASES OF GENITAL AND HARVES, INCLUDING PREMATURE WALKING AND LEIOMYOME
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
EP1799264A2 (en) * 2004-10-08 2007-06-27 Neuromolecular Pharmaceuticals Inc Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
JP2008526923A (ja) * 2005-01-13 2008-07-24 ノイロサーチ アクティーゼルスカブ 新規８−置換８−アザ−ビシクロ［３．２．１］オクタン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのそれらの使用
BRPI0607017B8 (pt) * 2005-04-06 2021-05-25 Adamas Pharmaceuticals Inc composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
AU2008272964A1 (en) * 2007-06-29 2009-01-08 Emory University NMDA receptor antagonists for neuroprotection
NO2303330T3 (hu) * 2008-06-06 2018-04-14
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
KR20140146217A (ko) * 2012-04-20 2014-12-24 유씨비 파마, 에스.에이. 파킨슨병을 치료하는 방법
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3116475B1 (en) 2014-03-13 2020-11-04 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
WO1991012005A1 (en) 1990-02-06 1991-08-22 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
US5455250A (en) 1991-04-18 1995-10-03 Pfizer Inc. Prodrug esters of phenolic 2-piperidino-1-alkanols
DE4118740A1 (de) 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson

Also Published As

Publication number Publication date
CZ283979B6 (cs) 1998-07-15
DE69532482D1 (de) 2004-02-26
MX9709112A (es) 1998-02-28
WO1996037226A2 (en) 1996-11-28
PT828513E (pt) 2004-05-31
PL314413A1 (en) 1996-12-09
NO962130D0 (no) 1996-05-24
US6258827B1 (en) 2001-07-10
FI974323A0 (fi) 1997-11-25
TW470740B (en) 2002-01-01
RU2176145C2 (ru) 2001-11-27
SG45479A1 (en) 1998-01-16
CO4700422A1 (es) 1998-12-29
CZ152496A3 (cs) 1998-04-15
NZ286656A (en) 2001-03-30
HUP9601419A2 (en) 1997-09-29
DE69532482T2 (de) 2004-11-25
BR9602485A (pt) 1998-04-22
IL118328A (en) 2001-06-14
EP0828513A2 (en) 1998-03-18
CA2219911A1 (en) 1996-11-28
CN1159325A (zh) 1997-09-17
WO1996037226A3 (en) 1996-12-27
NO962130L (no) 1996-11-27
AU696258B2 (en) 1998-09-03
CA2219911C (en) 2004-07-27
FI974323A (fi) 1997-11-25
EP0828513B1 (en) 2004-01-21
IL118328A0 (en) 1996-09-12
AU5451996A (en) 1996-12-05
TR199600436A2 (tr) 1996-12-21
HUP9601419A3 (en) 1998-01-28
DK0828513T3 (da) 2004-04-13
JPH11505828A (ja) 1999-05-25
ES2211904T3 (es) 2004-07-16
ATE258067T1 (de) 2004-02-15

Similar Documents

Publication Publication Date Title
HU9601419D0 (en) Synergetic pharmaceutical compositions for treating parkinson-disease
Upton Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings
KR100521829B1 (en) Compositions and Methods for the Treatment of Alzheimer's Disease, Central Nervous System Injury, and Inflammatory Diseases
BR9709501A (pt) Composto, composição farmacêutica , e, processos para tratar ou prevenir a esquizofrrenia e para sintetizar um composto
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
EP0659078A4 (en) ANABASEIN DERIVATIVES FOR TREATING DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM.
HUT62337A (en) New cyclosporins, pharmaceutical compositions comprising such compounds and process for producing same
IL128723A0 (en) Pharmaceutical compositions containing rar antagonists and rxr agonists
IL141263A0 (en) Methods for treatment of neurological disorders
IL117824A (en) Pharmaceutical compositions containing 2-aryl-imidazol¬1,2-a¾pyridine-3-acetamide derivatives for treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia
BG106065A (en) Method for the treatment of neurological or neuropsychiatric disorders
ATE205480T1 (de) 2,5-dioxo-2,5-dihydro-1h-benz(b)azepine als nmda rezeptor antagonisten
AUPP674898A0 (en) A method of treatment
EP0435177A3 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
MY118944A (en) Synergistic treatment for parkinsonism
MY121206A (en) Aminobenzamide compounds for the treatment of neurodegenerative disorders
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
WO1994024279A3 (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
EP0900567A3 (en) Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
MA26474A1 (fr) Derives de quinoxalinedione, procede pour leur preparation et compositions pharmaceutiques les contenant .
HUT59004A (en) Process for applying the interleukine-1 biosynthesis of 3-substituted-2-oxyndole-derivatives carried out as inhibitor
BR9909791A (pt) Tratamento de distúrbios de ansiedade de modo geral com a partoxetina